media1

Group News

Aspen’s profit after tax increases by 35%

March 3, 2016

Aspen’s profit after tax increases by 35% Johannesburg – JSE Limited listed Aspen Pharmacare Holdings Limited (APN), a leading pharmaceutical manufacturer in the southern hemisphere, has announced pleasing results for the six months ended 31 December 2015. The Group delivered solid growth in a period marked by economic stress and weakening market currencies. The factors…

Read More >>

Aspen’s revenue increases 22% to R36 billion

September 9, 2015

Johannesburg – JSE Limited listed Aspen Pharmacare Holdings Limited (APN), the sixth largest generic company in the world, has announced excellent results for the year ended 30 June 2015. These results benefitted from the contribution of acquisitions concluded during the prior year. GROUP PERFORMANCE Revenue increased by 22% to R36.1 billion. Operating profit rose by…

Read More >>

Divestment of portfolio of branded and generic products to Strides entities

May 21, 2015

Aspen is pleased to announce that certain of its wholly owned Australian subsidiaries (collectively “Aspen Australia”), have entered into an agreement with Strides (Australia) Pharma Pty Ltd (“Strides Australia”), a company incorporated in Australia, in terms whereof Aspen Australia will divest to Strides Australia, a portfolio of approximately 130 products for a consideration of approximately…

Read More >>

Cautionary Announcement

May 14, 2015

Shareholders are advised that Aspen is currently engaged in discussions regarding a possible acquisition of an infant nutritionals business. These discussions may have a material effect on the price of Aspen’s securities if successfully concluded and accordingly shareholders are advised to exercise caution when dealing in the Company’s securities. Durban 14 May 2015 Sponsor                                                                         Investec…

Read More >>

Divestment of South African Business Unit to Litha

May 11, 2015

Aspen is pleased to announce that Pharmacare Limited (“Pharmacare”), a wholly owned subsidiary of Aspen Holdings and the Group’s primary South African trading company, has concluded a set of agreements with Litha Pharma (Pty) Ltd (“Litha”) (a wholly owned South African subsidiary of Endo International Plc) in terms which Pharmacare will divest a business unit…

Read More >>

Gauteng Premier’s visit to Aspen is set to boost export growth

May 7, 2015

Clayville, Johannesburg – JSE Limited listed Aspen Pharmacare Holdings Limited (APN), the 5th largest generic company in the world, earlier today hosted a delegation of over 30 government dignitaries at its manufacturing facility where specialised infant nutritional products are produced for local and export markets. The facility is unique in that it contains highly specialized…

Read More >>

Aspen opposes violent attacks directed at fellow African migrants

April 28, 2015

Statement by Stephen Saad, Group CEO, Aspen Pharmacare Holdings Ltd “Aspen” on the violent attacks directed at fellow African migrants living in South Africa Durban – Aspen, largest producer and supplier of medicines to our African continent, in the strongest terms condemns the shameful and senseless harassment and violence directed at fellow African migrants, in…

Read More >>

GSK announces completion of the sale of half its stake in Aspen

March 13, 2015

GlaxoSmithKline (“GSK”) has announced the completion of the disposal of half of its 12.4% shareholding in Aspen (equivalent to 28.2 million ordinary shares). These shares were sold by means of an accelerated book build offering process which resulted in the shares being sold at ZAR 372 per share, raising gross proceeds of approximately ZAR 10.5…

Read More >>

Aspen’s half-year gross revenue surges by 47% to R19 billion

March 5, 2015

Aspen’s half-year gross revenue surges by 47% to R19 billion Johannesburg – JSE Limited listed Aspen Pharmacare Holdings Limited (APN), the fifth largest generic company in the world, has announced stellar results for the six months ended 31 December 2014, which have primarily been driven by its offshore businesses. GROUP PERFORMANCE Gross revenue increased by…

Read More >>

Acquisition of rights to an anti-coagulant product from Novartis

January 26, 2015

Aspen is pleased to announce that Aspen Global Incorporated (“AGI”), a wholly owned subsidiary of Aspen Holdings, has entered into an agreement with Novartis AG in terms of which it will acquire the rights to Mono-Embolex®, an injectable anti-coagulant, for a consideration of US$142.3 million. Mono-Embolex is a heparin based anti-coagulant sold in the same…

Read More >>